RyboDyn raised $10 million in seed funding to accelerate oncology target discovery by exploring the “dark proteome,” including cryptic peptides derived from non-canonical RNA sources. The company says its platform integrates deep sequencing of non-canonical RNAs with proteome detection, then uses AI models to identify disease-specific, druggable protein targets. RyboDyn’s CypherAtlas database reportedly holds data from roughly 1,000 patient tumors across 10 cancer indications, alongside information on millions of uncharacterized RNAs and tens of thousands of cryptic peptides identified by mass spectrometry. The company also cited an in vitro killing result against tumor cells via a cryptic protein target and reported discovery of a novel cryptic target in roughly 45% of HER2-negative breast cancer tumors. The financing includes participation from Genedant, SeaX Ventures, SOSV, Swell VC, Massive Tech Ventures, and P2V. RyboDyn plans to use the funding to translate targets into early therapies, including potential internal programs and partner-led development. For investors, the round emphasizes continued capital flow into next-generation target discovery approaches that aim to expand beyond conventional antigen biology in oncology.